Point72 Asset Management
CAPR icon

Point72 Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Point72 Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$949K – 2218
2025
Q1 		$949K Buy
+100,000
New +$1.39M ﹤0.01% 1466

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management's CAPR Position: Q2 2026 in Review

Point72 Asset Management reduced its Capricor Therapeutics (CAPR) stake by 88% in Q2 2026, selling an estimated $22M and leaving 94,723 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2306.

Point72 Asset Management first reported a position in CAPR in Q3 2024 and has held it in 5 quarters since. The position peaked at $53.1M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Point72 Asset Management held 94,723 shares of Capricor Therapeutics worth $2.28M as of Q2 2026.
  • Point72 Asset Management sold 726,456 Capricor Therapeutics shares in Q2 2026, an estimated $22M.
  • Capricor Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #2306 holding.
  • Point72 Asset Management first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Point72 Asset Management's Capricor Therapeutics position peaked at $53.1M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.